S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
S&P 500   3,958.55 (-0.13%)
DOW   33,702.29 (-0.23%)
QQQ   284.37 (+0.18%)
AAPL   143.04 (+0.27%)
MSFT   246.31 (-0.44%)
META   115.49 (+0.14%)
GOOGL   93.95 (+0.26%)
AMZN   89.61 (-0.82%)
TSLA   180.66 (+4.16%)
NVDA   174.26 (+1.50%)
NIO   13.00 (-3.06%)
BABA   93.14 (-1.09%)
AMD   69.89 (-0.82%)
T   19.24 (+0.63%)
MU   55.43 (+0.42%)
CGC   3.10 (+0.32%)
F   13.27 (+1.14%)
GE   82.36 (-1.52%)
DIS   94.03 (+1.60%)
AMC   6.05 (-0.33%)
PYPL   74.11 (-0.15%)
PFE   52.01 (+0.44%)
NFLX   325.44 (+4.89%)
NASDAQ:DARE

Daré Bioscience - DARE Stock Forecast, Price & News

$0.90
+0.01 (+1.12%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
$0.93
50-Day Range
$0.89
$1.05
52-Week Range
$0.88
$2.14
Volume
113,747 shs
Average Volume
203,065 shs
Market Capitalization
$76.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
900.3% Upside
$9.00 Price Target
Short Interest
Healthy
1.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.25) to ($0.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

Medical Sector

897th out of 1,022 stocks

Pharmaceutical Preparations Industry

442nd out of 499 stocks

DARE stock logo

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

H.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)
Dare inaugurates NBBF board
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings
11/10/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DARE
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+455.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-38,700,000.00
Pretax Margin
-245.47%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.51 per share

Miscellaneous

Free Float
81,432,000
Market Cap
$76.31 million
Optionable
Not Optionable
Beta
1.17

Key Executives

  • Ms. Sabrina Martucci Johnson (Age 55)
    Pres, CEO, Sec. & Director
    Comp: $643.48k
  • Ms. Lisa Walters-Hoffert (Age 63)
    Chief Financial Officer
    Comp: $439.33k
  • Mr. John A. Fair (Age 50)
    Chief Strategy Officer
    Comp: $435.83k
  • Mr. Mark Walters (Age 67)
    VP of Operations
  • Ms. MarDee J. Haring-Layton (Age 46)
    VP of Accounting & Fin.
  • Dr. David Friend
    Chief Scientific Officer













DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DARE shares.
View DARE analyst ratings
or view top-rated stocks.

What is Daré Bioscience's stock price forecast for 2023?

4 brokers have issued 1 year target prices for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they expect the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 900.3% from the stock's current price.
View analysts price targets for DARE
or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2022?

Daré Bioscience's stock was trading at $2.00 at the beginning of 2022. Since then, DARE shares have decreased by 55.0% and is now trading at $0.8997.
View the best growth stocks for 2022 here
.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our DARE earnings forecast
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same quarter in the previous year, the company posted ($0.24) earnings per share.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

What is Daré Bioscience's stock symbol?

Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Who are Daré Bioscience's major shareholders?

Daré Bioscience's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.17%), Renaissance Technologies LLC (0.77%), Founders Financial Securities LLC (0.41%), Price T Rowe Associates Inc. MD (0.15%), Virtu Financial LLC (0.08%) and UBS Group AG (0.07%).
View institutional ownership trends
.

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Daré Bioscience's stock price today?

One share of DARE stock can currently be purchased for approximately $0.90.

How much money does Daré Bioscience make?

Daré Bioscience (NASDAQ:DARE) has a market capitalization of $76.31 million. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Daré Bioscience?

Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 12/9/2022 by MarketBeat.com Staff